Schwarzmitchell6780

To study the safety and efficacy of bi-optics using Implantable Collamer lens (ICL) followed by SMILE for management of extreme myopia.

Nethradhama Superspeciality Eye Hospital, Bangalore, India.

Retrospective case series METHODS Data was analysed for patients who underwent bi-optics using ICL in the first stage, and SMILE in the second stage for correction of the residual refractive error. Mean interval between stage 1 and stage 2 correction was 24.2±13.33 days. Mean follow-up after the SMILE procedure was 12.26±1.39 (11-14) months.

Fifteen eyes from 9 patients with mean age 26±4.69 years were included. Pre-operatively, mean SE was-22.89±3.04 D (-16.50 to -28.00D), which decreased to -3.40±1.89 D after ICL, and further reduced to -0.48±0.24 D after final correction with SMILE, at the end of the mean follow-up. Mean cylinder reduced from -2.88± 1.69 D to -1.93±1.07D post ICL, and-0.38±0.24D post SMILE surgery. Mean CDVA significantly improved from 0.38± 0.22 to 0.068±0.09 LogMAR after SMILE correction (p=0.00). Mean UDVA at the end of follow-up was 0.15±0.09 LogMAR with all eyes achieving UDVA of ≥0.3LogMAR.All eyes had gain in CDVA with 53% eyes gaining 2 or more lines. No wound, intraocular pressure or ICL related complications were observed during and after the SMILE surgery. No patient required spectacles, contact lenses or enhancement for further improvement of vision.

Bi-optics with SMILE following ICL implantation may be a valid option for extremely myopic patients resulting in significant improvements in visual acuity and high patient satisfaction.

Bi-optics with SMILE following ICL implantation may be a valid option for extremely myopic patients resulting in significant improvements in visual acuity and high patient satisfaction.

The aim of this study was to evaluate the efficacy, safety and predictability of transepithelial photorefractive keratectomy (TransPRK) for correcting myopia, astigmatism and hyperopia.

Department of Ophthalmology, Saarland University Medical Center, Homburg/Saar, Germany DESIGN Meta-analysis of retrospective or prospective studies METHODS Relevant studies were collected from Medline and included when meeting the following predefined criteria randomized controlled trials, at least one of main outcome measures efficacy, safety or predictability and one common TRPK laser ("Schwind Amaris"). The parameters estimates and 95% confidence intervals (CI) were derived from random-effects meta-analysis to account for possible heterogeneity.

Since hyperopia studies did not meet the inclusion criteria, the results are centered around myopia and astigmatism. Sixteen studies with a total of 1,924 treated eyes were included in the meta-analysis. The mean efficacy, safety and predictability had a probability of 94% CI=0.86-0.97, 0% CI= 0.00-0.03 and 89% CI=0.82-0.93, respectively. The mean correction index, difference vector and index of success had a value of 1.01 CI=1.01-1.02, 0.2 CI=0.06-0.34 and 0.12 CI=0.07-0.18, respectively.

This summary estimate shows that the TransPRK is highly effective, safe and predictable in correcting myopia and/or astigmatism.

This summary estimate shows that the TransPRK is highly effective, safe and predictable in correcting myopia and/or astigmatism.

The purpose of this study was to identify patterns of depressive symptom trajectory and examine the associations of the symptom trajectory with caregiving burden, family function, social support, and perceived health status of caregivers of stroke survivors during the first year of caregiving after discharge from rehabilitation center.

Caregivers of stroke survivors completed a survey of depressive symptoms, caregiving burden, family function, perceived availability of social support, and perceived health status at postdischarge and 1 year. Patterns of depressive symptom trajectory (ie, symptom-free, symptom relieved, symptom developed, and persistent symptom groups) were identified by grouping depressive symptoms based on 2 assessments using the Center for Epidemiologic Studies-Depression. this website Repeated-measures analysis of variance and multinomial logistic regression were used to examine the associations.

Of the 102 caregivers, 57.8% were symptom-free, 20.6% experienced persistent depressive symptoms, 11.8r of caregiving from discharge for stroke survivors.

We investigated the distribution of pathogens on stool gastrointestinal (GI) polymerase chain reaction (PCR) testing in those who subsequently developed inflammatory bowel disease (IBD).

Infectious gastroenteritis has been associated with later development of IBD.

This retrospective study includes patients of all ages hospitalized for diarrhea with positive GIPCR panel and subsequently a new diagnosis of IBD [confirmed by chart review and International Classification of Disease, Clinical Modification code for Crohn's disease (CD) or ulcerative colitis (UC)], between March 2015 to September 2019 at our quaternary care institution. Patients with IBD diagnosis before GIPCR were excluded. Descriptive statistics characterized the distribution of microbial pathogens in relation to later IBD diagnosis.

Fifty-four participants were eligible (UC 44%; CD 56%). Median age at time of IBD diagnosis was 35 years [interquartile range (IQR) 18 to 65]. Median time between GIPCR and IBD diagnosis was 3 months (IQR 2 to 9) for all patients. When stratified by organism class, median time to diagnosis was 6 months (IQR 2 to 10) for patients with bacteria, 3 months (IQR 1 to 8) for patients with viruses, and 1 month (IQR 0.75 to 1) for patients with parasites (log-rank P=0.001). Sixty-nine unique pathogens (83% bacteria) were identified on all tests. Escherichia coli was the most common species (71%), of which enteropathogenic E. coli was predominant (38%).

The E. coli species, specifically enteropathogenic E. coli, may be implicated in the development of IBD. This is one of the first studies to evaluate the results of stool GIPCR in the link between the microbiome and IBD pathogenesis.

The E. coli species, specifically enteropathogenic E. coli, may be implicated in the development of IBD. This is one of the first studies to evaluate the results of stool GIPCR in the link between the microbiome and IBD pathogenesis.